Loading...
•
Sep 30, 2021
BioCryst Q3 2021 Earnings Report
BioCryst reported strong Q3 2021 financial results driven by ORLADEYO revenue and provided a corporate update.
Key Takeaways
BioCryst announced Q3 2021 financial results, with total revenues of $41.0 million, primarily driven by $37.0 million in ORLADEYO net revenue. The company expects full-year 2021 ORLADEYO net revenue to be between $115 million and $120 million.
Q3 2021 revenue reached $41.0 million.
ORLADEYO net revenue was $37.0 million in Q3 2021.
Full year 2021 ORLADEYO net revenue is expected to be $115-$120 million.
Operating cash use for the third quarter of 2021 was $18.8 million.
Forward Guidance
BioCryst expects full year 2021 net ORLADEYO revenue to be between $115 million and $120 million and believes their current cash runway takes them into 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...